Overview

* Madrigal Q3 revenue rises to $287.3 mln, driven by Rezdiffra demand

* Company reports a net loss for Q3 despite revenue growth

* Madrigal closes global licensing deal with CSPC Pharma for oral GLP-1

Outlook

* Madrigal expects Rezdiffra sales to grow in 2026

* Company plans to start clinical trials for oral GLP-1 in H1 2026

* Rezdiffra patent protection extends to 2045

Result Drivers

* REZDIFFRA DEMAND - Increased demand for Rezdiffra drives Q3 revenue growth to $287.3 mln

* GLOBAL LICENSING DEAL - Madrigal closed a global licensing agreement with CSPC Pharma for an oral GLP-1 receptor agonist

* GERMANY LAUNCH - Madrigal launched Rezdiffra in Germany following European Commission approval

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $287.26

Product mln

Revenue

Q3 EPS -$5.08

Q3 Net -$114.19

Income mln

Q3 $401.24

Operatin mln

g

Expenses

Q3 -$113.97

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Madrigal Pharmaceuticals Inc ( MDGL ) is $524.50, about 21.4% above its November 3 closing price of $412.35

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)